Visit Reservation
中
The COVID-19 nucleic acid detection kit has been completed by the GDMV star enterprise- Genetron recently. It is submitted to the National Drug Administration (NMPA) 5 for approval. After approval, 100 thousand people will be donated to Beijing.
At the same time, Genetron quickly completed the R&D of kits and testing services and the construction of its production service system, guaranteed the daily output of kits of 10000-15000 people, and ensured that its laboratories output 2000 people of testing services per day, which helped epidemic prevention and control from kits to testing services.
Technical advantages of the kit
Fast:
Using the one-step technology, the RNA reverse transcription and QPCR reaction are combined into a single tube reaction, combined with the rapid temperature rise and fall of the supporting equipment, the fastest 45 minutes to complete the reverse transcription and PCR amplification.
High Accuracy:
The detection is as low as 10 copies, which improves the sensitivity and can achieve a higher detection rate. At the same time, specific amplification and fluorescence detection of the target area are carried out, and endogenous internal reference is involved in the reaction in each detection tube. Effective quality control is carried out throughout the testing process to reduce false negatives and false positives.
Large-scale Testing Can be Carried Out to Improve Laboratory Efficiency:
The kit uses one-step technology to meet the large-scale testing of a large number of samples, maximize the release of molecular laboratory testing capabilities and improve the efficiency of epidemic prevention and control.
In addition, based on the high-throughput sequencing technology platform-GENETRON S5 (National Machinery Standard Note 20193220820), Genetron Biosciences is developing a one-time detection kit for 32 kinds of respiratory pathogens including COVID-19, which provides the country's infectious and major disease prevention and control capabilities Enhance contribution.
Beijing Genetron Gene Technology Co., Ltd.
As a pioneer in the field of precision oncology medicine in China, Beijing Genetron Gene Technology Co., Ltd. adheres to the full-cycle R&D concept of "exploration, discovery, application, and change", and adheres to "6 quality control nodes, 5 major dimensions of control, and 3 sets of quality control strategies. ”Full-cycle quality control system to provide users with full-cycle testing services from “scientific research to clinical”. Genetron Health has dual R&D centers in China and the United States, 4 medical testing laboratories with a total area of more than 10,000 square meters, and have passed CAP and CLIA dual certification. Genetron Health also has an industry-renowned, multidisciplinary team of experts with academic background covering cancer genomics, bioinformatics, pharmacology, clinical pathology and other fields.
